Metrics as of 10/14/2026, 03:41 PM (Berlin time), refresh in progress.
CG Oncology Stock
CG Oncology Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Arthur Kuan
- Employees
- 142
- Market cap
- $5.5 B
- IPO
- 25/01/2024
CG Oncology Inc. is a late-stage clinical biopharmaceutical company focused on the development and commercialization of cretostimogene grenadenorepvec for patients with bladder cancer in the United States. Founded in 2010, the company is headquartered in Dallas and went public on January 25, 2024, on the NASDAQ. With…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
CG Oncology stock: price history
1D
-0.9%
1W
-0.9%
1M
-16.2%
6M
-8.6%
YTD
+48.9%
1Y
+44.3%
2Y
+64.8%
5Y
–
10Y
–
Next earnings date
Next earnings date
13/11/2026 (in 27 days)
Volatility around earnings
~7% stronger price swings than usual
CG Oncology stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 17/10/2026.
Business model & megatrends
Robust business model that benefits noticeably from at least one megatrend.
CG Oncology Inc. is a late-stage biopharmaceutical company developing and commercializing an oncolytic immunotherapy against bladder cancer with cretostimogene grenadenorepvec. Phase 2 and Phase 3 clinical trials are investigating the safety and efficacy of the drug candidate in patients with high-risk non-muscle invasive bladder cancer following BCG therapy failure. The company currently generates revenues exclusively through licensing and collaboration agreements.
- Revenue model
- Transactional
- Recurring revenue
- None
- Pricing power
- Strong
- Moat
- Narrow
- Moat type
- Brand / IP
- Capital intensity
- High
- Customer concentration
- Unknown
Ask the agents about CG Oncology
Analyst assessment of CG Oncology
PRICE TARGET LOW
US$80.00
CONSENSUS
US$86.50
MEDIAN
US$83.00
PRICE TARGET HIGH
US$100.00
0
STRONG BUY
10
BUY
0
HOLD
0
SELL
0
STRONG SELL
10
TOTAL · Buy
As of: 07/08/2026
CG Oncology stock metrics
P/E
-22.9
P/B
5.3
EV/EBITDA
-24.7
RETURN ON EQUITY
-7.7%
NET MARGIN
-6,832.8%
DEBT/EQUITY
0.01
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
74.6%
FLOAT SHARES
65,823,742
AVG. DAILY VOLUME (30D)
958,109
Insider transactions (SEC)
POST LEONARD E
POST LEONARD E
POST LEONARD E
POST LEONARD E
POST LEONARD E
Institutional holders
Comparable stocks
Frequently asked questions about CG Oncology stock
What does CG Oncology do?
CG Oncology Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Arthur Kuan, the company employs around 142 people.
The IPO was on 25/01/2024; the stock trades on NASDAQ under the ticker CGON.
What do analysts say about CG Oncology stock?
10 analysts rate the stock, the consensus is Buy (as of 07/08/2026).
The average price target is US$86.50, ranging from US$80.00 to US$100.00, with a median of US$83.00.
This is an external assessment, not a statement by Market Jury.
When does CG Oncology report next?
The next earnings date is 13/11/2026.
Around past earnings, price swings were roughly 7% stronger than usual.
Does CG Oncology pay a dividend?
No, CG Oncology currently does not pay a dividend.
Which stocks are comparable to CG Oncology?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get CG Oncology stock analyzed?
Clicking "Analyze stock" lets five strategies assess CG Oncology against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.